Major Milestone Treatment Completed in P3 Trial for CLBP
Filed with ASX · · 3 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
- Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
- Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
Later from Mesoblast
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- FDA Approves New Potency Assay for Commercial Ryoncil
- MSB Reports Increased Revenue and Improved Operating Spend
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast